Daisy Alapat Institution-verified

Sourced from institutional research profiles (UAMS TRI or ARA).

Researcher

UAMS

Last publication 2025 Last refreshed 2026-05-16

faculty

17 h-index 106 pubs 1,655 cited

Research Areas

Links

ORCID Lab Website Research Group UAMS TRI Profile

Edit your profile

OverviewAI-generated summary

Daisy Alapat's research focuses on Castleman disease, investigating treatment outcomes, disease burden, and comorbidities. She has published work characterizing the heterogeneity of Castleman disease, including the oligocentric subtype, using data from the ACCELERATE registry. Her publications also explore the effectiveness of various treatment regimens, including rituximab and siltuximab, and their impact on disease progression and patient outcomes. Alapat's work has examined the increased comorbidities and hospitalizations associated with idiopathic multicentric Castleman disease and explored variable response rates across different chemotherapy regimens for severe forms of the disease. Her research extends to pediatric idiopathic multicentric Castleman disease, noting its severity and response to specific treatments.

Metrics

h-index: 17
Publications: 106
Citations: 1,655

Selected Publications

Illuminating Blurry Vision: Visualization of Corneal Protein Deposition With Immunofluorescence in Two Illustrative Case Reports (2026)

DOI OpenAlex
Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma (2026)

DOI OpenAlex
Breast-implant associated unicentric castleman disease: a case report (2026)

DOI OpenAlex
Elucidating the grading intricacies of idiopathic multicentric Castleman disease histopathology: a pathologist’s perspective (2025)

DOI OpenAlex
Pediatric idiopathic multicentric castleman disease is often severe and responds to siltuximab (2025)

DOI OpenAlex
Equal survival for Black Americans with multiple myeloma when appropriately matched to White Americans (2025)

DOI OpenAlex
When less is more: the role of non-vitrectomized vitreous surgery in retinal diseases (2025)

DOI OpenAlex
Prognostic impact of focal lesion location and persistence in multiple myeloma: insights from serial PET/DWI imaging (2025)

DOI OpenAlex
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma (2025)

1 citation DOI OpenAlex
Variable response rates across chemotherapy regimens for severe idiopathic multicentric Castleman disease. (2025)

1 citation DOI OpenAlex
Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registry (2025)

13 citations DOI OpenAlex
Unveiling Myelodysplastic Syndromes: Exploring Pathogenic Mechanisms and Therapeutic Advances (2025)

3 citations DOI OpenAlex
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma (2024)

5 citations DOI OpenAlex
The Development of Diagnostic Criteria and Utilization of Excisional Lymph Node Biopsies Shorten Time to Diagnosis for Idiopathic Multicentric Castleman Disease (2024)

2 citations DOI OpenAlex
The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans (2024)

DOI OpenAlex